fibrin and Urinary-Incontinence

Endoscopic injection of bulking agents has been widely used to treat urinary incontinence, often due to urethral sphincter complex insufficiency. The aim of the study was to develop a novel injectable bioactive collagen-fibrin bulking agent restoring long-term continence by functional muscle tissue regeneration. Fibrin micro-beads were engineered using a droplet microfluidic system. They had an average diameter of 140 μm and recombinant fibrin-binding insulin-like growth factor-1 (α. Urinary incontinence is involuntary urine leakage, resulting from a deficient function of the sphincter muscle complex. Yet there is no functional cure for this devastating condition using current treatment options. Applied physical and surgical therapies have limited success. In this study, a novel bioactive injectable bulking agent, triggering new muscle regeneration at the injection site, has been evaluated. This injectable consists of cross-linked collagen and fibrin micro-beads, functionalized with bound insulin-like growth factor-1 (α

Topics: Animals; Cell Movement; Cell Survival; Collagen; Cross-Linking Reagents; Elastic Modulus; Fibrin; Humans; Injections; Insulin-Like Growth Factor I; Microfluidics; Microspheres; Myocytes, Smooth Muscle; Particle Size; Rats; Rheology; Urinary Incontinence; Viscosity